TL;DR
Get self-care and calm essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Researchers at Albert Einstein College of Medicine report that restoring chaperone-mediated autophagy (CMA), a cellular protein-recycling process, reduced senescent-cell buildup in aged mice. The study, published in Nature Aging, also found less severe lung fibrosis in treated animals, but it does not establish that the approach is safe or effective in people.
Restoring chaperone-mediated autophagy (CMA), a process cells use to break down and recycle selected proteins, reduced the buildup of senescent cells in aged mice and lessened signs of lung fibrosis, researchers at Albert Einstein College of Medicine report in a study published October 5 in Nature Aging. The findings point to a possible way to help the body clear these cells, but the reported treatment results are from animals, not a clinical trial in people.
The researchers examined why senescent cells—sometimes called “zombie cells”—can accumulate with age. These cells remain alive but stop dividing or functioning normally. While they can have useful roles, including signaling during wound repair, their persistence can disrupt surrounding tissue and contribute to inflammation and disease.
In experiments with mice, the team found that CMA activity fell with age in both senescent cells and macrophages, immune cells that help remove them. When CMA was lacking in macrophages, mice accumulated more senescent cells at wound sites and healed more slowly than control animals. Laboratory tests also showed that senescent cells from older mice did not increase CMA activity as cells from young mice did. They released substances that, according to the researchers, encouraged nearby cells to become senescent and made macrophages less able to recognize and clear them.
The team then tested CA77.1, a small-molecule CMA activator it had previously developed. Five months of daily oral treatment in aged mice reduced senescent-cell buildup in several organs and lowered signs of inflammation and fibrosis. In a separate experiment, treating macrophages taken from aged mice restored their ability to engulf particles to levels comparable to those of macrophages from young mice. The study also included analyses of human lung tissue, but those analyses do not show that CA77.1 benefits patients.
A Different Route to Clearing Senescent Cells
The results suggest that age-related cell buildup may reflect more than the persistence of senescent cells themselves: the immune cells tasked with clearing them may also lose effectiveness. If that relationship holds in people, treatments that support CMA could potentially address both the harmful activity of senescent cells and the ability of macrophages to remove them.
That would differ from approaches focused only on senolytic drugs, which are designed to eliminate senescent cells. The study does not show that CMA activation is a better treatment or that it can prevent age-related disease in humans. Instead, it offers a biological mechanism and a candidate strategy for further testing, with lung fibrosis providing one disease-related outcome in the mouse experiments.
As an affiliate, we earn on qualifying purchases.
How Aging May Disrupt Cellular Cleanup
CMA is a form of cellular recycling in which chaperone molecules identify selected proteins and direct them for breakdown. Study leader Ana Maria Cuervo, a professor at Einstein, has previously investigated how CMA declines with age and how reduced activity can allow damaged or unwanted proteins to build up in cells.
Senescent cells are not always harmful. During wound healing, they can release signals that recruit cells involved in repair; they are normally cleared after their temporary role. The new experiments examined what happens when the recycling process is impaired in both senescent cells and macrophages, and whether restoring CMA changes that balance. Most of the study was conducted in mice, while human lung-tissue analyses offered evidence of possible relevance to people rather than proof of a human treatment effect.
senescent cell removal supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Human Benefits Remain Unproven
The supplied report does not establish whether CA77.1 is safe or effective in people, what dose might be appropriate, or whether the mouse findings translate to human diseases such as idiopathic pulmonary fibrosis. The human lung-tissue analyses do not answer those treatment questions, and the report provides no clinical-trial results.
It is also unclear from the available details how the compound’s effects might vary across diseases, tissues, or stages of aging, or what risks could arise from altering CMA over time. The animal results support further investigation, but they do not show that cellular recycling can be restored in patients or that doing so would prevent or reverse age-related illness.
As an affiliate, we earn on qualifying purchases.
Testing the Approach Beyond Mice
The next step is additional research to establish whether the findings can guide treatment studies in people. Researchers would need to assess the compound’s safety, dosing, and effects in human cells and then determine whether clinical trials are warranted. The report identifies idiopathic pulmonary fibrosis as a possible disease area for examining relevance, but it does not report a planned or ongoing patient trial.
Until human evidence is available, CA77.1 should be understood as an experimental compound and the reported benefits as findings in aged mice. Future work will need to show whether activating CMA can reduce senescent-cell effects in people without unacceptable risks.
lung fibrosis treatment supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What are senescent, or “zombie,” cells?
Senescent cells are living cells that have stopped dividing. They can serve temporary functions, such as helping signal during wound repair, but lingering cells may disrupt tissue and contribute to inflammation.
What did the study find?
The researchers reported that restoring CMA activity reduced senescent-cell buildup in aged mice and lessened signs of lung fibrosis. They also found that the process affected macrophages’ ability to clear senescent cells.
Was CA77.1 tested in people?
The supplied report describes tests in aged mice and laboratory work with macrophages from mice. It does not report a clinical trial or demonstrate that CA77.1 is safe or effective in humans.
Does the research show that this approach treats lung fibrosis?
No. The study reported less severe signs of fibrosis in treated mice. It does not establish a treatment for lung fibrosis in people or show that the compound can prevent or reverse the disease in patients.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
